Frederick Munschauer from EMD Serono: Rebif Continues to Show Strong Results in Multiple Sclerosis Treatment

While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.

Frederick E. Munschauer, MD, from EMD Serono discussed the medication which was first approved 14 years ago and is still a popular choice among clinicians looking to help patients with relapsing remitting multiple sclerosis. Munschauer discussed the topic during the annual meeting of the Consortium of Multiple Sclerosis Centers in National Harbor Maryland.